-
Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studie
Author: Senna, Maryanne; Soung, Jennifer; Figueras, Ignasi; King, Brett; Kinoshita-Ise, Misaki; Hanna, Sameh; Wu, Wenyu; Wajsbrot, Dalia; Woodworth, Deborah; Wolk, Robert; Chaudhry, Alanna; Lejeune, Alexandre; Tran, Helen
Journal: AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2026; Vol. , Issue , pp. -. DOI: 10.1007/s40257-026-01029-y
-
Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis After Inadequate Response to Dupilumab: Efficacy and Safety Results from Period 2 of Phase 3b/4 Study (LEVEL UP
Author: Bunick, Christopher G.; Magnolo, Nina; Moore, Angela; Abe, Masatoshi; Gao, Xinghua; Lynde, Charles; Ibrahim, Nadia; Levy, Gweneth; Calimlim, Brian M.; Wu, Xiaoqiang; Armendariz, Yolanda; Grada, Ayman; Eyerich, Kilian
Journal: AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2026; Vol. , Issue , pp. -. DOI: 10.1007/s40257-025-01003-0
-
Upadacitinib Dose Reduction Regimen in Elderly Patients with Atopic Dermatitis, Guided by Treat-to-Target Consensus Recommendation
Author: Tong, Zequn; Zeng, Xueting; Huang, Fuchen; Wu, Zhenlan; Chen, Huayu; Zhang, Yihua; Chen, Jiawen; Luo, Renwei; Chen, Fa; Zou, Ying; Ji, Chao; Gong, Ting
Journal: AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2025; Vol. , Issue , pp. -. DOI: 10.1007/s40257-025-00923-1
-
The Impact of Family History on Clinical Presentation and Biologic Treatment Response in Patients with Psoriasis: A Multicenter Prospective Cohort Stud
Author: Jiang, Yuxiong; Liu, Xiaoke; Ma, Rui; Huang, Dawei; Wang, Yu; Zhong, Xiaoyuan; Yao, Lingling; Xu, Shuang; Li, Ying; Zhang, Xilin; Lu, Jiajing; Shi, Yuling
Journal: AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2025; Vol. , Issue , pp. -. DOI: 10.1007/s40257-025-00918-y
